• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏多糖贮积症 II 型患者的听力损失:来自 HOS-亨特结果调查的数据。

Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.

机构信息

Department of ORL, Langenbeckstr. 1 Gebäude 102, 55131, Mainz, Germany.

出版信息

J Inherit Metab Dis. 2012 Mar;35(2):343-53. doi: 10.1007/s10545-011-9378-5. Epub 2011 Aug 25.

DOI:10.1007/s10545-011-9378-5
PMID:21866356
Abstract

BACKGROUND

Subjectively reported hearing loss is a common feature of mucopolysaccharidosis II (MPS II, Hunter syndrome). This study provides an epidemiological description of hearing loss and other otolaryngological manifestations reported by patients registered in the Hunter Outcome Survey (HOS), an international registry of patients with MPS II.

METHODS

Data about ear signs and symptoms were available for 554 of the 605 patients alive at HOS entry. The degree of hearing loss for 162 pure-tone audiograms (PTAs) from 83 patients was classified by independent interpreters using both the age-specific International Institute of Standardization (ISO) 7029 standard and the age-independent World Health Organization (WHO) clinical guidelines. A linear regression analysis using cross-sectional data was conducted to investigate the relationship between hearing loss and age.

RESULTS

The most prevalent otolaryngological manifestations and interventions reported were otitis (either acute otitis media or chronic otitis media [72%]), hearing loss (67%), insertion of ventilation tubes (50%), adenoidectomy (47%), and hearing aids (41%). According to the ISO standard, only one patient out of the 83 with audiogram data in HOS had normal hearing in both ears at all time points. According to the WHO classification, 16% had normal hearing; hearing loss was mild in 24%, moderate in 31%, severe in 22%, and profound in 7%. In the linear regression analysis, the hearing threshold in the cohort increased with age at an estimated rate of approximately 1 dB per year.

CONCLUSIONS

Hearing impairment is common in MPS II. Early otolaryngological evaluation and intervention is recommended.

摘要

背景

主观报告的听力损失是黏多糖贮积症 II 型(MPS II,亨特综合征)的常见特征。本研究对亨特结果调查(HOS)中登记的 MPS II 患者报告的听力损失和其他耳鼻喉科表现进行了流行病学描述,HOS 是一个国际 MPS II 患者注册处。

方法

在 HOS 入组时,有 605 名存活患者中有 554 名提供了有关耳部体征和症状的数据。83 名患者的 162 个纯音听力图(PTA)的听力损失程度由独立解释者使用年龄特异性国际标准化组织(ISO)7029 标准和年龄无关的世界卫生组织(WHO)临床指南进行分类。使用横断面数据进行线性回归分析,以调查听力损失与年龄之间的关系。

结果

报告的最常见耳鼻喉科表现和干预措施是中耳炎(急性中耳炎或慢性中耳炎[72%])、听力损失(67%)、通气管插入(50%)、腺样体切除术(47%)和助听器(41%)。根据 ISO 标准,在 HOS 中有听力图数据的 83 名患者中,只有 1 名患者在所有时间点双耳听力均正常。根据 WHO 分类,16%听力正常;16%为轻度听力损失,24%为中度听力损失,31%为重度听力损失,7%为深度听力损失。在线性回归分析中,队列中的听力阈值以每年约 1dB 的速度随年龄增加而增加。

结论

听力障碍在 MPS II 中很常见。建议早期进行耳鼻喉科评估和干预。

相似文献

1
Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.黏多糖贮积症 II 型患者的听力损失:来自 HOS-亨特结果调查的数据。
J Inherit Metab Dis. 2012 Mar;35(2):343-53. doi: 10.1007/s10545-011-9378-5. Epub 2011 Aug 25.
2
Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis.61例黏多糖贮积症患者的耳鼻咽喉科表现
Int J Pediatr Otorhinolaryngol. 2020 Aug;135:110137. doi: 10.1016/j.ijporl.2020.110137. Epub 2020 May 27.
3
Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses.通过纯音测听评估黏多糖贮积症患者的听力损失。
Mol Genet Metab. 2014 Apr;111(4):533-8. doi: 10.1016/j.ymgme.2014.02.003. Epub 2014 Feb 16.
4
Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children.用于治疗儿童渗出性中耳炎所致听力损失的鼓膜通气管(通风管)
Cochrane Database Syst Rev. 2005 Jan 25(1):CD001801. doi: 10.1002/14651858.CD001801.pub2.
5
Hearing loss in Hunter's syndrome--mucopolysaccharidosis II.
Ear Hear. 1984 Jul-Aug;5(4):243-6. doi: 10.1097/00003446-198407000-00009.
6
Otologic and audiologic findings in 22q11.2 deletion syndrome.22q11.2缺失综合征的耳科和听力学表现
Eur Arch Otorhinolaryngol. 2017 Feb;274(2):765-771. doi: 10.1007/s00405-016-4365-y. Epub 2016 Nov 11.
7
Auditory Characteristics in Patients With Mucopolysaccharidosis.黏多糖贮积症患者的听觉特征
Otol Neurotol. 2019 Dec;40(10):e955-e961. doi: 10.1097/MAO.0000000000002422.
8
Audiometric evaluation in individuals with mucopolysaccharidosis.黏多糖贮积症患者的听力测定评估
Clinics (Sao Paulo). 2018 Dec 3;73:e523. doi: 10.6061/clinics/2018/e523.
9
First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).西班牙5岁以下亨特综合征患者使用艾度硫酸酯酶进行酶替代治疗的首次经验:来自亨特结果调查(HOS)的病例观察
Eur J Med Genet. 2010 Nov-Dec;53(6):371-7. doi: 10.1016/j.ejmg.2010.07.013. Epub 2010 Aug 10.
10
Pure tone hearing profiles in children with otitis media with effusion.儿童分泌性中耳炎的纯音听力图。
Disabil Rehabil. 2018 May;40(10):1166-1175. doi: 10.1080/09638288.2017.1290698. Epub 2017 Feb 25.

引用本文的文献

1
Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey.黏多糖贮积症II型成年患者未满足的需求:来自亨特结果调查的数据。
Orphanet J Rare Dis. 2025 Jul 1;20(1):319. doi: 10.1186/s13023-024-03464-8.
2
Hearing Loss in Mucopolysaccharidosis.黏多糖贮积症中的听力损失
Int Arch Otorhinolaryngol. 2021 Jul;25(3):e386-e391. doi: 10.1055/s-0040-1712107. Epub 2020 Sep 24.
3
Differences in MPS I and MPS II Disease Manifestations.黏多糖贮积症 I 型和 II 型临床表现的差异。

本文引用的文献

1
Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey.手术史在诊断黏多糖贮积症 II 型(亨特综合征)中的重要性:来自亨特预后调查的数据。
Genet Med. 2010 Dec;12(12):816-22. doi: 10.1097/GIM.0b013e3181f6e74d.
2
Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses.儿科耳鼻喉科医生在黏多糖贮积症患儿诊断和管理中的作用。
Int J Pediatr Otorhinolaryngol. 2010 Jan;74(1):27-31. doi: 10.1016/j.ijporl.2009.09.042. Epub 2009 Nov 20.
3
Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey.
Int J Mol Sci. 2021 Jul 23;22(15):7888. doi: 10.3390/ijms22157888.
4
Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series.莫尔基奥A综合征及酶替代疗法对不同年龄组土耳其患者的影响:病例系列
Orphanet J Rare Dis. 2021 Mar 22;16(1):144. doi: 10.1186/s13023-021-01761-0.
5
Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.黏多糖贮积症中的听力损失:当前认知与未来方向
Diagnostics (Basel). 2020 Aug 4;10(8):554. doi: 10.3390/diagnostics10080554.
6
Hearing loss in patients with mucopolysaccharidoses-1 and -6 after hematopoietic cell transplantation: A longitudinal analysis.黏多糖贮积症 1 型和 6 型患者造血细胞移植后听力损失:一项纵向分析。
J Inherit Metab Dis. 2020 Nov;43(6):1279-1287. doi: 10.1002/jimd.12277. Epub 2020 Jul 9.
7
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations.静脉内酶替代疗法治疗黏多糖贮积症:临床疗效和局限性。
Int J Mol Sci. 2020 Apr 23;21(8):2975. doi: 10.3390/ijms21082975.
8
Assessing the impact of the five senses on quality of life in mucopolysaccharidoses.评估五感对黏多糖贮积症患者生活质量的影响。
Orphanet J Rare Dis. 2020 Apr 19;15(1):97. doi: 10.1186/s13023-020-01368-x.
9
Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome-Type II Mucopolysaccharidosis.经耳道入路对一名患有II型黏多糖贮积症(亨特综合征)青少年进行人工耳蜗植入术
J Audiol Otol. 2021 Jan;25(1):49-54. doi: 10.7874/jao.2019.00325. Epub 2019 Dec 10.
10
Otolaryngologists and the Early Diagnosis of Mucopolysaccharidoses: A Cross-Sectional Study.耳鼻喉科医生与黏多糖贮积症的早期诊断:一项横断面研究。
Diagnostics (Basel). 2019 Nov 13;9(4):187. doi: 10.3390/diagnostics9040187.
儿童法布瑞病的耳部症状:来自法布瑞病结局调查的数据。
J Inherit Metab Dis. 2009 Dec;32(6):739. doi: 10.1007/s10545-009-1290-x. Epub 2009 Oct 27.
4
Hearing Impairment in 2008: a compilation of available epidemiological studies.2008 年听力障碍:现有流行病学研究汇编。
Int J Audiol. 2009;48(7):473-85. doi: 10.1080/14992020902803120.
5
Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.亨特氏病的神经学表现:病理学及可能的治疗效果综述
J Inherit Metab Dis. 2008 Aug;31(4):473-80. doi: 10.1007/s10545-008-0878-x. Epub 2008 Jul 13.
6
Initial report from the Hunter Outcome Survey.猎人结果调查的初步报告。
Genet Med. 2008 Jul;10(7):508-16. doi: 10.1097/gim.0b013e31817701e6.
7
Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).黏多糖贮积症II型(亨特综合征)的识别与诊断。
Pediatrics. 2008 Feb;121(2):e377-86. doi: 10.1542/peds.2007-1350.
8
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).艾度硫酸酯酶用于黏多糖贮积症II型(亨特综合征)酶替代疗法的II/III期临床研究。
Genet Med. 2006 Aug;8(8):465-73. doi: 10.1097/01.gim.0000232477.37660.fb.
9
Cumulative incidence rates of the mucopolysaccharidoses in Germany.德国黏多糖贮积症的累积发病率
J Inherit Metab Dis. 2005;28(6):1011-7. doi: 10.1007/s10545-005-0112-z.
10
Otorhinolaryngological manifestations of the mucopolysaccharidoses.黏多糖贮积症的耳鼻咽喉科表现。
Int J Pediatr Otorhinolaryngol. 2005 May;69(5):589-95. doi: 10.1016/j.ijporl.2005.01.017.